Global Consortium for Biomarker Standardization


At a Glance
  • Status: Active Consortium
  • Year Launched: 2010
  • Initiating Organization: Alzheimer's Association
  • Initiator Type: Nonprofit foundation
  • Disease focus:
    Alzheimer's Disease
  • Location: North America

Abstract

The Alzheimer’s Association has established the Global Consortium for Biomarker Standardization to gather key researchers, clinicians, and industry, regulatory, and government leaders in Alzheimer’s disease (AD) to achieve consensus on the best ways to standardize and validate biomarker tests for use in clinical practices around the world.

Mission

The Consortium will continue to grow and expand as the field identifies novel technologies and techniques for diagnosis of AD. To date, projects are addressing the following:

Impact/Accomplishment

July 7, 2011: Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, et al. Alzheimer’s & Dementia. The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers.

Homepage

http://www.alz.org/research/funding/global_biomarker_consortium.asp

Points of Contact

Maria C. Carrillo, Ph.D.
Vice President, Medical & Scientific Relations
Alzheimer's Association
email: maria.carrillo@alz.org

Sponsors & Partners

Alzheimer's Association


Last Updated: 04/18/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.